In English | En español
Questions About Cancer? 1-800-4-CANCER

NCI Drug Dictionary


Cipro  
(Other name for: ciprofloxacin)

ciprofloxacin  
A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication. This agent is more active against Gram-negative bacteria than Gram-positive bacteria. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Circadin  
(Other name for: therapeutic melatonin)

cis-urocanic acid  
A derivative of the amino acid histidine, formed in the mammalian skin from trans-urocanic acid upon ultraviolet radiation, and protodynamic agent, with potential anti-inflammatory and antiproliferative activity. Upon intravesical instillation of cis-urocanic acid (cis-UCA), this agent is protonated at the imidazolyl moiety in the mildly acidic extracellular tumor environment and penetrates into the cancer cell. Once inside the cell and due to the slightly alkaline pH inside the tumor cell, cis-UCA is deprotonated, i.e. the imidazolyl proton is released into the cytosol which eventually raises the intracellular acidity. This acidification impairs many cellular processes, such as metabolic activity, and may lead to cell cycle arrest, an induction of cellular apoptosis and necrotic cell death. In addition, cis-UCA enhances ERK and JNK signaling pathways by inhibiting the activity of serine/threonine and tyrosine phosphatases. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cisatracurium besylate  
A non-depolarizing skeletal muscle relaxant of the benzylisoquinolinium class. Cisatracurium besylate acts as a competitive acetylcholine antagonist that binds to nicotinic receptors at the neuromuscular junction. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action. Cisatracurium besylate is used to maintain neuromuscular relaxation during major surgical procedures, primarily to facilitate endotracheal intubation. Cisatracurium besylate can cause bronchospasms, hypotension, and bradycardia. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cisplatin  
An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cisplatin-e therapeutic implant  
An injectable collagen matrix gel containing the inorganic platinum agent cisplatin and the sympathicomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, cisplatin alkylates guanine nucleosides in DNA, and causes DNA-DNA or DNA-protein cross-linkages, thereby preventing DNA replication and resulting in tumor cell growth inhibition and apoptosis. Epinephrine, a potent vasoconstrictor, is added to the gel to enhance penetration of cisplatin into tumor tissue and reduce dispersion into the surrounding tissues. Intratumoral injection of cisplatin-E therapeutic implant may increase local chemotherapeutic efficacy compared to the systemic administration of these agents while reducing systemic toxicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Cistane  
(Other name for: isotretinoin)

citalopram hydrobromide  
The orally bioavailable hydrobromide salt of the racemic bicyclic phthalene derivative citalopram with antidepressant activity. As a selective serotonin reuptake inhibitor (SSRI), citalopram selectively inhibits the CNS neuronal reuptake of serotonin, thereby potentiating serotonergic activity in the central nervous system (CNS). This agent has minimal effects on the CNS neuronal reuptake of norepinephrine (NE) and dopamine (DA). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

citatuzumab bogatox  
A fusion protein immunotoxin consisting of a humanized, single-chain monoclonal antibody Fab fragment specific for the epithelial cell adhesion molecule (EpCAM) conjugated with a modified bouganin cytotoxin with potential antineoplastic activity. Citatuzumab bogatox binds to EpCAM, delivering modified bouganin cytotoxin directly to EpCam-positive tumor cells, which may result in the inhibition of tumor cell protein synthesis and tumor cell death. EpCAM, a cell surface protein, is expressed by a variety of tumor cells and is frequently found in head and neck cancers. Bouganin is a plant-derived ribosome-inactivating protein (RIP), a toxic plant N-glycosidase that depurinates the universally conserved alpha-sarcin loop of ribosomal rRNA, inactivating the ribosome and preventing protein synthesis. Compared to unmodified bouganins, modified bouganins may have a reduced propensity to activate human T cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

citicoline  
A nutritional supplement and source of choline and cytidine with potential neuroprotective and nootropic activity. Citicoline, also known as cytidine-5-diphosphocholine or CDP-choline, is hydrolyzed into cytidine and choline in the intestine. Following absorption, both cytidine and choline are dispersed, utilized in various biosynthesis pathways, and cross the blood-brain barrier for resynthesis into citicoline in the brain, which is the rate-limiting product in the synthesis of phosphatidylcholine. This agent also increases acetylcholine (Ach), norepinephrine (NE) and dopamine levels in the central nervous system (CNS). In addition, citicoline is involved in the preservation of sphingomyelin and cardiolipin and the restoration of Na+/K+-ATPase activity. Citicoline also increases glutathione synthesis and glutathione reductase activity, and exerts antiapoptotic effects. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Citracal  
(Other name for: calcium citrate)

Citroma  
(Other name for: magnesium citrate)

cixutumumab  
A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

CK2-targeting synthetic peptide CIGB-300  
A synthetic peptide targeting the substrates of casein kinase 2 (CK2), with potential antineoplastic activity. Upon administration and nucleolar localization, CK2-targeting synthetic peptide CIGB-300 binds to phosphoacceptor sites on the CK2’s substrates, in particular the oncoprotein nucleophosmin (B23 or NPM1). This blocks the activation of B23 and induces apoptosis, thereby inhibiting tumor cell growth in susceptible tumor cells. CK2, a protein kinase often overexpressed in a variety of cancer cell types, appears to be correlated with malignant transformation, tumor growth and survival. Overexpression of B23 has been correlated with increased cellular growth and proliferation as well as inhibition of differentiation and apoptosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cladribine  
A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis. Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Clafen  
(Other name for: cyclophosphamide)

Claforan  
(Other name for: cefotaxime)

Claravis  
(Other name for: isotretinoin)

Clarinol  
(Other name for: conjugated linoleic acid)

clarithromycin  
A semisynthetic 14-membered ring macrolide antibiotic. Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms. Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Class 1 PI3K kinase family inhibitor XL147  
An orally bioavailable small molecule, targeting the class I phosphatidylinositol 3 kinase (PI3K) family of lipid kinases, with potential antineoplastic activity. Class 1 PI3K kinase family inhibitor XL147 reversibly binds to class 1 PI3Ks in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K signaling pathway; this may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents including genotoxic agents and receptor tyrosine kinase inhibitors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

claudiximab  
A monoclonal antibody directed against the antigen GC182 with potential immunostimulatory and antineoplastic activities. Upon administration, claudiximab specifically binds to GC128, which may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GC182-expressing tumor cells, resulting in decreased tumor cell proliferation. The CD20-like antigen GC182, a gastric differentiation protein, is often overexpressed on the cell surfaces of a variety of tumor cells, including gastric, pancreatic, esophageal cancer and non-small cell lung cancer (NSCLC) cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

clevidipine butyrate injectable emulsion  
An injectable phospholipid emulsion containing the butyrate salt of the synthetic, short-acting, dihydropyridine L-type calcium channel antagonist clevidipine with antihypertensive activity. Clevidipine specifically binds to calcium channels in vascular smooth muscle cells, inhibiting the influx of extracellular calcium ions into vascular smooth muscle cells. This results in dilatation of systemic arteries, a decrease in systemic vascular resistance and so a decrease in arterial blood pressure. This agent is metabolized by esterases in the blood and extravascular tissues to an inactive carboxylic acid metabolite. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Cleviprex  
(Other name for: clevidipine butyrate injectable emulsion)

clevudine  
A synthetic pyrimidine analogue with activity against hepatitis B virus (HBV). Intracellularly, clevudine is phosphorylated to its active metabolites, clevudine monophosphate and triphosphate. The triphosphate metabolite competes with thymidine for incorporation into viral DNA, thereby causing DNA chain termination and inhibiting the function of HBV DNA polymerase (reverse transcriptase). Clevudine has a long half-life and shows significant reduction of covalently closed circular DNA (cccDNA), therefore the patient is less likely to have a relapse after treatment is discontinued. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

clindamycin/hydrocortisone lotion  
A topical lotion, containing clindamycin and hydrocortisone, with antibacterial and anti-inflammatory activities. Clindamycin, a lincomycin antibiotic, binds to the 50S subunit of the bacterial ribosome, thereby inhibiting bacterial protein synthesis. As a glucocorticoid agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppression of immune and inflammatory responses. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Clino-San vaginal lubricant  
A vaginal lubricant formulated as a topical gel used to prevent and treat vaginal dryness. With a pH similar to that of normal vaginal discharge, Clino-San vaginal lubricant may reduce dryness, pain and irritation often caused by insufficient vaginal discharge due to atrophy of the vulvovaginal mucosa. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Clinoril  
(Other name for: sulindac)

clioquinol  
An orally bioavailable, lipophilic, copper-binding, halogenated 8-hydroxyquinoline with antifungal, antiparasitic and potential antitumor activities. Clioquinol forms a stable chelate with copper (copper (II) ions), which inhibits the chymotrypsin-like activity of the proteasome; consequently, ubiquitinated proteins may accumulate in tumor cells, followed by tumor cell apoptosis and the inhibition of tumor angiogenesis. In addition, the clioquinol-copper complex appears to decrease the expression of androgen receptors (AR) in human copper-enriched prostate cancer cells. Serum levels of copper are often elevated in patients with cancer; copper chelation may inhibit copper-dependent endothelial cell proliferation and tumor secretion of angiogenic factors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

clobetasol propionate  
The propionate salt form of clobetasol, a topical synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

clodronate disodium  
The disodium salt of a nitrogen-free bisphosphonate analog of naturally occurring pyrophosphate. Clodronate binds to calcium and inhibits osteoclastic bone resorption and hydroxyapatite crystal formation and dissolution, resulting in a reduction of bone turnover. This agent may control malignancy-associated hypercalcemia, inhibit osteolytic bone metastasis and decrease pain. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

clofarabine  
A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5'-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factor, which activate apoptosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Clofarex  
(Other name for: clofarabine)

clofibrate  
An aryloxyisobutyric acid derivate with antihyperlipidemic activity. Although the exact mechanism of action has not been fully characterized, clofibrate may enhance the conversion of very-low-density lipoprotein (VLDL) to low-density lipoprotein (LDL), decreasing the production of hepatic VLDL, inhibiting cholesterol production, and increasing fecal excretion of neutral sterols. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Clolar  
(Other name for: clofarabine)

Clomid  
(Other name for: clomiphene citrate)

clomiphene citrate  
The citrate salt form of clomiphene, a triphenylethylene nonsteroidal ovulatory stimulant evaluated for antineoplastic activity against breast cancer. Clomiphene has both estrogenic and anti-estrogenic activities that compete with estrogen for binding at estrogen receptor sites in target tissues. This agent causes the release of the pituitary gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to ovulation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

clonidine hydrochloride  
The hydrochloride salt form of clonidine, an imidazoline derivate and centrally-acting alpha-adrenergic agonist as well as antagonist with antihypertensive activity. Clonidine hydrochloride binds to and stimulates central alpha-2 adrenergic receptors, thereby decreasing sympathetic outflow to the heart, kidneys, and peripheral vasculature. The reduction in sympathetic outflow, leads to decreased peripheral vascular resistance, decreased blood pressure, and decreased heart rate. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Clonidine Lauriad  
(Other name for: clonidine-containing mucoadhesive buccal tablet)

clonidine-containing mucoadhesive buccal tablet  
An extended release, proprietary mucoadhesive buccal tablet formulation containing the hydrochloride salt form of clonidine, the imidazoline derivative and adrenergic alpha 2 receptor agonist, with anti-inflammatory activity. Upon contact of the tablet with the buccal mucosa, clonidine binds to the adrenergic receptors on macrophages and lymphocytes and may reduce the release of pro-inflammatory mediators such as tumor necrosis factor alpha (TNFalpha). As a result, this agent may prevent chemoradiation therapy-induced mucositis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

clopidogrel bisulfate  
A thienopyridine with antiplatelet activity. Clopidogrel bisulfate irreversibly alters the platelet receptor for adenosine diphosphate (ADP), thereby blocking the binding of ADP to its receptor, inhibiting ADP-mediated activation of the glycoprotein complex GPIIb/IIIa, and inhibiting fibrinogen binding to platelets and platelet adhesion and aggregation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Cloretazine  
(Other name for: laromustine)

Clostridium novyi-NT spores  
Spores of Clostridium novyi-NT, an attenuated strain of the obligate anaerobe Clostridium novyi, with potential immunostimulating and oncolytic activities. Upon intravenous administration, Clostridium novyi-NT spores germinate exclusively in hypoxic tissue, such as avascular regions of tumors. Germination results in lysis and destruction of surrounding viable tumor cells. Although C. novyi-NT spores do not proliferate in oxygenated tumor regions, they may stimulate the immune system to mount a cytolytic immune response against tumor cells, both hypoxic and well-oxygenated. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

clotrimazole  
A synthetic, imidazole derivate with broad-spectrum, antifungal activity. Clotrimazole inhibits biosynthesis of sterols, particularly ergosterol, an essential component of the fungal cell membrane, thereby damaging and affecting the permeability of the cell membrane. This results in leakage and loss of essential intracellular compounds, and eventually causes cell lysis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

CMF regimen  
A chemotherapy regimen consisting of cyclophosphamide, methotrexate, and fluorouracil, which may be used in the adjuvant setting for the treatment of nonmetastatic breast cancer or alone for the treatment of metastatic breast cancer. (NCI Thesaurus)

CMV pp65 peptide  
A peptide derived from cytomegalovirus (CMV) internal matrix protein pp65. CMV pp65 peptide antigen is used in recombinant vaccinia virus as an HLA-A-restricted epitope to produce vaccines and specific CD8+ and CD4+ cell responses against CMV infection, a serious complication of allogeneic bone marrow transplantation (BMT). In BMT, CMV infection may be prevented by passive immunization with donor-derived CMV-pp65-specific T-cell clones if provided early post-BMT. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

CMVpp65-A*0201 peptide vaccine  
A peptide-based cancer vaccine containing a mutated form of the HLA-A*0201-restricted cytomegaloviral epitope CMVpp65(495-503) with potential immunostimulatory and antitumor activities. Upon subcutaneous administration, CMVpp65-A*0201 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against CMV-positive cells, resulting in cell lysis. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. CMVpp65, a tegument protein of the herpes virus CMV, is the main viral antigen found in peripheral blood mononuclear cells (PBMCs) after viral infection and may activate cell-mediated immunity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

CNDO-109-activated allogeneic natural killer cells  
A preparation of non-interleukin-2 primed, tumor activated allogeneic natural killer (NK) cells with potential immunostimulating activity. The allogeneic NK cells obtained from a first or second degree relative of the patient are co-incubated with a lysate from the CTV-1 cell line, a minimally differentiated myeloid line derived from an acute myelogenous leukemia patient. Infusion of CNDO-109-activated allogeneic NK cells may be able to lyse and destroy NK-resistant tumor cells and a broad spectrum of tumor cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

CNGRC peptide-TNF alpha conjugate  
A cytokine-peptide conjugate composed of the cytokine tumor necrosis factor alpha (TNF-alpha) chemically linked to the peptide CNGRC. The peptide moiety CNGRC, a ligand for the membrane-bound metalloprotease CD13, binds to endothelial cells of the angiogenic vasculature that express CD13 (also known as aminopeptidase N); subsequently, the TNF-alpha moiety induces apoptosis in endothelial cells expressing CD13, thereby inhibiting tumor-associated angiogenesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Co-Rax  
(Other name for: warfarin)

Cocculus/nux vomica/tabacum/petroleum extract  
A homeopathic herbal formulation with potential anti-emetic activity. Cocculus/nux vomica/tabacum/petroleum extract contains equal homeopathic units of the following extracts: extract of Cocculus indicus (fish berry), the fruit of the southeast Asian/Indian climbing plant Anamirta cocculus; extract of the seeds of Strychnos nux vomica (poison nut), an evergreen tree native to southeast Asia; extract of Nicotiana tabacum (tobacco); and petroleum. Although the exact mechanism(s) of action for this formulation has yet to be fully elucidated, alkaloids in these plant extracts have been shown to relieve nausea, vomiting, and, in some cases, dizziness. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

codeine phosphate  
The phosphate salt of codeine, a naturally occurring phenanthrene alkaloid and opioid agonist with analgesic, antidiarrheal and antitussive activities. Codeine mimics the actions of endogenous opioids by binding to the opioid receptors at many sites within the central nervous system (CNS). Stimulation of mu-subtype opioid receptors results in a decrease in the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline; in addition, the codeine metabolite morphine induces opening of G-protein-coupled inwardly rectifying potassium (GIRK) channels and blocks the opening of N-type voltage-gated calcium channels, resulting in hyperpolarization and reduced neuronal excitability. Stimulation of gut mu-subtype opioid receptors results in a reduction in intestinal motility and delayed intestinal transit times. Antitussive activity is mediated through codeine’s action on the cough center in the medulla. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

coenzyme Q10  
A naturally occurring benzoquinone important in electron transport in mitochondrial membranes. Coenzyme-Q functions as an endogenous antioxidant; deficiencies of this enzyme have been observed in patients with many different types of cancer and limited studies have suggested that coenzyme-Q may induce tumor regression in patients with breast cancer. This agent may have immunostimulatory effects. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

CoFactor  
(Other name for: folitixorin)

colchicine  
An alkaloid isolated from Colchicum autumnale with anti-gout and anti-inflammatory activities. The exact mechanism of action by which colchicine exerts its effect has not been completely established. Colchicine binds to tubulin, thereby interfering with the polymerization of tubulin, interrupting microtubule dynamics, and disrupting mitosis. This leads to an inhibition of migration of leukocytes and other inflammatory cells, thereby reducing the inflammatory response to deposited urate crystals. Colchicine may also interrupt the cycle of monosodium urate crystal deposition in joint tissues, thereby also preventing the resultant inflammatory response. Overall, colchicine decreases leukocyte chemotaxis/migration and phagocytosis to inflamed areas, and inhibits the formation and release of a chemotactic glycoprotein that is produced during phagocytosis of urate crystals. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cold contaminant-free iobenguane I 131  
An I 131 radioiodinated synthetic analogue of the neurotransmitter norepinephrine, manufactured with a proprietary process, with radioisotopic and potential antineoplastic activities. cold contaminant-free iobenguane I 131 (MIBG) localizes to adrenergic tissue and may be used to image or eradicate tumor cells that accumulate and metabolize norepinephrine. This agent is manufactured using a technology that avoids the production of unwanted "cold contaminants" (i.e., carrier molecules), which may cause undesirable side effects and compete with MIBG for binding on target receptor sites. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

COLD-fX  
(Other name for: North American ginseng extract AFX-2)

collagen/aloe vera/vitamin E/lidocaine topical hydrogel  
A topical preparation containing collagen, aloe vera, vitamin E, and lidocaine hydrochloride with wound-healing activity. The four ingredients of collagen/aloe vera/vitamin E/lidocaine topical hydrogel may promote wound repair and new tissue growth in which : collagen, a structural protein in connective tissue, provides a connective tissue matrix for the attachment of various cells involved in wound repair; aloe vera carbohydrate polymers provide a moist wound environment; vitamin E promotes blood vessel formation; and lidocaine acts as a local anesthetic. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

colloidal gold-bound tumor necrosis factor  
A nanoparticle delivery system for recombinant human tumor necrosis factor (TNF) consisting of recombinant TNF bound to pegylated colloidal gold nanoparticles with potential antineoplastic activity. Upon intravenous administration, colloidal gold-bound recombinant human TNF travels through the bloodstream, avoiding immune detection and uptake by the reticuloendothelial system because of nanoparticle pegylation. Due to their size, the colloidal gold nanoparticles exit the circulatory system only at hyperpermeable tumor neovasculature sites; TNF then binds to and activates tumor cell TNF receptors, which may result in an increase in tumor cell apoptosis and a reduction in tumor cell proliferation. Compared to the administration of unbound TNF, colloidal gold-bound TNF may improve the efficacy and safety of TNF administration by delivering TNF specifically to tumor tissue. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

colloidal oatmeal cream  
A colloidal oatmeal-based skin cream with potential moisturizing and skin protecting activity. Upon application to the skin, colloidal oatmeal cream forms a protective barrier and thereby prevents water loss, provides moisture to the skin and protects the skin from damage. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Colprosterone  
(Other name for: therapeutic progesterone)

Combidex  
(Other name for: ferumoxtran-10)

Combotox  
(Other name for: deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins)

combretastatin A1 diphosphate  
The diphosphate prodrug of the stilbenoid combretastatin A1, originally isolated from the plant Combretum caffrum, with vascular-disrupting and antineoplastic activities. Upon administration, combretastatin A1 diphosphate (CA1P) is dephosphorylated to the active metabolite combretastatin A1 (CA1), which promotes rapid microtubule depolymerization; endothelial cell mitotic arrest and apoptosis, destruction of the tumor vasculature, disruption of tumor blood flow and tumor cell necrosis may ensue. In addition, orthoquinone intermediates, metabolized from combretastatin A1 by oxidative enzymes found to be elevated levels in some tumor types, may bind to tumor cell thiol-specific antioxidant proteins and DNA, and stimulate oxidative stress by enhancing superoxide/hydrogen peroxide production. CA1 binds to tubulin at the same site as colchicine but with higher affinity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Commit  
(Other name for: nicotine lozenge)

Compound 42  
(Other name for: warfarin)

conatumumab  
A fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Concentraid  
(Other name for: desmopressin acetate)

Concerta  
(Other name for: methylphenidate hydrochloride)

conditionally replicative adenovirus 5/3-delta24  
A replication competent, oncolytic adenovirus serotype 5 (Ad5) with its knob domain of fiber protein substituted by that of the serotype 3 (Ad5/3-delta24), with potential oncolytic activity. Upon administration, oncolytic adenovirus Ad5/3-delta24 binds to specific Ad3 receptors that are highly expressed on certain tumor cells. This results in the replication of oncolytic adenovirus Ad5/3-delta24 in tumor cells and induces tumor cell lysis which may potentially result in the activation of a systemic immune response against tumor-associated antigens. The Ad5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene which allows for selective replication in cells that are defective in the retinoblastoma gene (Rb) or cyclin-dependent kinase inhibitor-2A (CDKN2A or p16INK4a). As most tumor cells are defective in the Rb/p16 pathway, this virus selectively replicates in these cells. The replacement of the Ad5 fiber knob, which mediates viral-cell receptor binding, allows for a Coxsackie-adenovirus receptor (CAR)-independent infection of tumor cells; CAR expression is often deficient on cancer cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

conjugated estrogens  
Purified orally bioavailable female sex hormones isolated from pregnant mare urine or synthetically derived from plant materials and primarily conjugated as sulfate esters. Estrogen binds to and activates specific nuclear receptors, which, in turn, bind to estrogen response elements (EREs) in target genes, resulting in histone acetylation, alteration of chromatin conformation, and initiation of transcription. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

conjugated linoleic acid  
A slightly altered form of linoleic acid, an omega-6 fatty acid important to human health found in beef and dairy fats. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Constant-T  
(Other name for: theophylline)

COPP regimen  
A chemotherapy regimen consisting of cyclophosphamide, vincristine (Oncovin), procarbazine and prednisone used for the treatment of Hodgkin and non-Hodgkin lymphomas. (NCI Thesaurus)

copper Cu 64 TP3805  
A peptide analog of pituitary adenylate cyclase-activating peptide (PACAP) radiolabeled with the positron-emitting radioisotope copper Cu 64, with potential diagnostic ability upon positron emission tomography (PET) imaging. The peptide moiety of copper Cu 64 TP3805 is able to bind to vasoactive intestinal peptide/pituitary adenylate cyclase activating peptide receptors 1 (VPAC1). Upon PET imaging, the cancer cells expressing VPAC1 can be visualized and this may allow for early detection. The oncogenic product VPAC1 is overexpressed in a variety of cancer cell types, moreover, it is overexpressed in 100% of breast tumors at the onset of the cancer. Compared to other positron-emitting radioisotopes, Cu 64 has a longer half life. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

copper Cu 64 trastuzumab  
A diagnostic radioimmunoconjugate comprised of the recombinant humanized monoclonal antibody trastuzumab conjugated with the positron-emitting radioisotope copper Cu 64. Copper Cu 64 trastuzumab binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2), allowing the detection of HER2 distribution using positron emission tomography (PET). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

copper Cu 64-ATSM  
A radioconjugate consisting of a lipophilic copper(II)bis(thiosemicarbazone) labeled with the positron- and beta-emitting isotope (64)Cu with hypoxia-selective and antineoplastic activities. With a high membrane permeability and redox potential, copper Cu 64-ATSM is preferentially taken up by hypoxic cells compared to normoxic cells; the extent of retention in tissue is inversely related to the state of tissue oxygenation allowing the quantitation of tissue hypoxia by positron emission tomography (PET). In addition, the radioactive copper moiety of this agent may deliver a selective cytotoxic dose of beta radiation to hypoxic tumor cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

copper Cu 64-DOTA-anti-HER3 monoclonal antibody U3-1287  
A radioimmunoconjugate of the fully human monoclonal antibody against the third member of the epidermal growth factor receptor (EGFR), HER3 or ERBB3, conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with radioisotope copper Cu 64, with potential diagnostic properties upon positron emission tomography (PET) imaging and antineoplastic activity. The antibody moiety of copper Cu 64-DOTA-anti-HER3 monoclonal antibody U3-1287 binds to and blocks the activation of HER3, thereby resulting in the inhibition of EGFR-dependent PI3K/AKT signaling and the subsequent inhibition of cellular proliferation and differentiation. The Cu 64 moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER3-expressing tumor cells. HER3, which lacks the kinase domain conveying ligand-binding signaling by forming heterodimers with other EGFR members that have kinase activity, is frequently overexpressed in solid tumors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

copper Cu 64-DOTA-rituximab  
A radioimmunoconjugate containing rituximab, a recombinant chimeric murine/human antibody directed against the human CD20 antigen, conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with the radioisotope copper Cu 64 with potential diagnostic properties upon positron emission tomography (PET) imaging. The monoclonal antibody moiety of copper Cu 64-DOTA-Rituximab specifically binds to cell surface antigen CD20. Upon binding, the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of CD20-expressing tumor cells. CD20 is a non-glycosylated phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

copper Cu 64-DOTA-trastuzumab  
A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with the radioisotope copper Cu 64 with radioisotopic activity and potential use as an imaging agent. The trastuzumab moiety of copper Cu 64-DOTA-trastuzumab binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER2-expressing tumor cells. HER2, a tyrosine kinase and client protein of heat shock protein 90 (Hsp90), may be overexpressed on the cell surfaces of various tumor cell types. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

copper gluconate  
The orally bioavailable copper salt of D-gluconic acid. In addition to its roles as an enzyme cofactor for cytochrome C oxidase and superoxide dismutase, copper forms complexes with the thiocarbamate disulfiram (DSF) forming DSF-copper complexes, which enhances the DSF-mediated inhibition of the 26S proteasome; proteasome inhibition may result in inhibition of cellular protein degradation, cessation of cell cycle progression, inhibition of cellular proliferation, and the induction of apoptosis in susceptible tumor cell populations. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Cordarone  
(Other name for: amiodarone hydrochloride)

cordycepin  
A purine nucleoside antimetabolite and antibiotic isolated from the fungus Cordyceps militaris with potential antineoplastic activity. Cordycepin is an adenosine analogue, which is readily phosphorylated to its mono-, di-, and triphosphate intracellularly. Triphosphate cordycepin can be incorporated into RNA, and inhibits transcription elongation and RNA synthesis due to the absence of a hydroxyl moiety at the 3' position. Because it can be converted to an inactive metabolite by adenosine deaminase, this agent must be administered with an adenosine deaminase inhibitor in order to be effective. Cordycepin has displayed cytotoxicity against some leukemic cell lines in vitro. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Coreg  
(Other name for: carvedilol)

Coreg CR  
(Other name for: carvedilol phosphate extended-release capsule)

Corgard  
(Other name for: nadolol)

Coriolus versicolor extract  
An extract derived from the mushroom Coriolus versicolor, containing polysaccharide K (PSK) and polysaccharide-peptide (PSP), with potential immunomodulating and antineoplastic activities. Coriolus versicolor extract has been shown to stimulate the production of lymphocytes and cytokines, such as interferons and interleukins, and may exhibit antioxidant activities. However, the precise mechanism of action(s) of this agent is unknown. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Cort-Dome  
(Other name for: therapeutic hydrocortisone)

Cortalone  
(Other name for: prednisolone)

Cortef  
(Other name for: therapeutic hydrocortisone)

Cortenema  
(Other name for: therapeutic hydrocortisone)

corticorelin acetate  
A synthetic therapeutic agent which is chemically identical to or similar to the endogenous human corticotropin-releasing factor (hCRF). Synthesized in the hypothalamus, hCRF stimulates the anterior pituitary gland to secrete adrenocorticotropic hormone (ACTH). In cerebral edema, hCRF acts by impeding the flow of fluid from blood vessels into brain tissue, thereby decreasing edema and stabilizing intracranial pressure. This agent possesses anti-edema properties independent of adrenal gland function. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Cortispray  
(Other name for: therapeutic hydrocortisone)

Cortril  
(Other name for: therapeutic hydrocortisone)

Corynebacterium granulosum P40  
An insoluble fraction isolated from the bacterium Corynebacterium granulosum with potential cancer immunotherapeutic activity. As a non-specific immunostimulant, Corynebacterium granulosum P40 activates the reticulo-endothelial system; induces the production of certain cytokines; enhances macrophage activity; and potentiates a delayed-type hypersensitivity response when co-administered with an antigen. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Cosmegen  
(Other name for: dactinomycin)

Cotara  
(Other name for: iodine I 131 monoclonal antibody TNT-1/B)

Cotrim  
(Other name for: trimethoprim-sulfamethoxazole)

Coumadin  
(Other name for: warfarin)

coumarin  
O hydroxycinnamic acid. Pleasant smelling compound found in many plants and released on wilting. Has anticoagulant activity by competing with Vitamin K. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

coxsackievirus A21  
A naturally occurring enterovirus with potential antitumor activity. Upon intratumoral administration, coxsackievirus A21 targets and binds to intracellular adhesion molecule 1 (ICAM-1) and decay acceleration factor (DAF), both cell surface molecules that are both overexpressed on certain malignant cells. After entering the cells, coxsackievirus A21 replicates in these cancer cells, thereby causing cancer cell lysis. This results in a reduction of tumor cell growth. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Cozaar  
(Other name for: losartan potassium)

CP-724,714  
An orally bioavailable quinazoline with potential antineoplastic activity. CP-724,714 selectively binds to the intracellular domain of HER2, reversibly inhibiting its tyrosine kinase activity and resulting in suppression of tumor cell growth. HER2, a member of the epidermal growth factor receptor (EGFR) family, is overexpressed in many adenocarcinomas, particularly breast cancers. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

CpG oligodeoxynucleotide  
A synthetic oligodeoxynucleotide, containing unmethylated CpG motifs derived from bacterial DNA, with immunostimulatory activities. A CpG oligodeoxynucleotide (CpG ODN) binds to and activates a Toll-like receptor 9 (TLR9) and is taken up into cells by endocytosis; once internalized, it may activate numerous signaling transduction pathways resulting in the release of multiple cytokines. Through activation of TLR9, a CpG ODN can directly stimulate B-lymphocytes, dendritic and NK cells, resulting in an increase in innate immunity and antibody-dependant cell cytotoxicity (ADCC). Additionally, a CpG ODN can indirectly modulate T-cell responses, through the release of cytokines (IL-12 and IFN gamma), to induce a preferential shift to the Th1 (helper) phenotype resulting in enhanced CD8+ cellular cytotoxicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

CpG oligodeoxynucleotide GNKG168  
A synthetic, 21-mer, unmethylated CpG motif-based oligodeoxynucleotide (ODN), with immunostimulatory activity. CpG oligodeoxynucleotide GNKG168 binds to and activates Toll-like receptor 9 (TLR9) and is taken up into cells by endocytosis; once internalized, it may activate numerous signaling transduction pathways resulting in the release of multiple cytokines, such as immunoglobulins (Igs), interferons (IFNs), interleukins (ILs) and tumor necrosis factor (TNF). Through activation of TLR9, this ODN can directly stimulate B-lymphocytes, dendritic and natural killer (NK) cells, resulting in an increase in innate immunity and antibody-dependent cellular cytotoxicity (ADCC). In addition, through the release of IL-12 and IFN, this agent may induce a preferential shift to the T-helper 1(Th1) phenotype resulting in enhanced CD8+ T cell-mediated antitumor cytotoxicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

creatine monohydrate  
The monohydrate form of creatine similar or identical to endogenous creatine produced in the liver, kidneys, and pancreas. Creatine, in phosphate form, helps supply energy to muscle cells for contraction. After intense effort, when ATP deposits are depleted, creatine phosphate donates phosphate groups toward the fast synthesis of ATP. Dietary supplementation with creatine may improve muscle wasting associated with cancer and other chronic diseases. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

crenolanib  
An orally bioavailable small molecule, targeting the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Crenolanib binds to and inhibits PDGFR, which may result in the inhibition of PDGFR-related signal transduction pathways, and, so, the inhibition of tumor angiogenesis and tumor cell proliferation. PDGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Cristanaspase  
(Other name for: asparaginase)

Crixivan  
(Other name for: indinavir sulfate)

crizotinib  
An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

CRM1 nuclear export inhibitor KPT-330  
An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), with potential antineoplastic activity. CRM1 nuclear export inhibitor KPT-330 modifies the essential CRM1-cargo binding residue cysteine-528, thereby irreversibly inactivating CRM1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (TSPs), including p53, p21, BRCA1/2, pRB, FOXO, and other growth regulatory proteins. As a result, this agent, via the approach of selective inhibition of nuclear export (SINE), restores endogenous tumor suppressing processes to selectively eliminate tumor cells while sparing normal cells. CRM1, the major export factor for proteins from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

crolibulin  
A small molecule tubulin polymerization inhibitor with potential antineoplastic activity. Crolibulin binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of tubulin into microtubules, which may result in cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. As a vascular disruption agent (VDA), this agent also disrupts tumor neovascularization, which may result in a reduction in tumor blood flow and tumor hypoxia and ischemic necrosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

crystalline genistein formulation AXP107-11  
An orally available crystalline formulation of genistein, a soy-derived isoflavone and phytoestrogen with potential antineoplastic, chemosensitizing, and antioxidant activities. Similar to genistein, crystalline genistein formulation AXP107-11 increases expression of phosphatase and tensin homolog (PTEN), which deactivates protein kinase Akt and mitogen-activated protein kinases (MAPK1 and 3; ERK2 and 1), thereby disrupting PI3K/Akt signal transduction and inducing apoptosis. This agent also induces antioxidant enzymes through AMP-activated protein kinase (AMPK) activation, inhibits NF-kB activation and decreases inflammation response, thereby sensitizing tumors to chemotherapy. Compared to genistein itself, this crystalline formulation shows improved solubility and bioavailability. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

CTP-37-DT vaccine  
A vaccine composed of synthetic peptides derived from beta-human chorionic gonadotropin (hCG) conjugated to diphtheria toxoid. Vaccination with this peptide may elicit the host immune response against hCG-producing cancer cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Cubicin  
(Other name for: daptomycin)

Culturelle  
(Other name for: Lactobacillus rhamnosus GG)

Cuprenil  
(Other name for: penicillamine)

Cuprimine  
(Other name for: penicillamine)

curcumin  
A phytopolylphenol pigment isolated from the plant Curcuma longa, commonly known as turmeric, with a variety of pharmacologic properties. Curcumin blocks the formation of reactive-oxygen species, possesses anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation; and disrupts cell signal transduction by various mechanisms including inhibition of protein kinase C. These effects may play a role in the agent's observed antineoplastic properties, which include inhibition of tumor cell proliferation and suppression of chemically induced carcinogenesis and tumor growth in animal models of cancer. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

curcumin/green tea extract/Polygonum cuspidatum extract/soybean extract capsule  
An oral capsule containing curcumin, green tea extract, Polygonum cuspidatum extract, and soybean extract, with antioxidant and potential chemopreventive activities. The antioxidants in curcumin/green tea extract/Polygonum cuspidatum extract/soybean extract capsule bind to and neutraliize free-radicals, which may prevent their genotoxic and carcinogenic effects. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Curretab  
(Other name for: medroxyprogesterone)

custirsen sodium  
The eicosasodium salt of a mixed-backbone antisense oligodeoxynucleotide with chemosensitizing properties. Custirsen inhibits testosterone-repressed prostate message-2 (TRPM-2). Administration of custirsen abrogates the anti-apoptotic effect of TRPM-2, thereby sensitizing cells to chemotherapy and resulting in tumor cell death. TRPM-2 is an anti-apoptotic clusterin that is overexpressed by prostate cancer cells and is associated with chemoresistance. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

CVP regimen  
A chemotherapy regimen consisting of cyclophosphamide, vincristine and prednisone used for the treatment of indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia. (NCI Thesaurus)

CXCR4 antagonist BKT140  
An orally bioavailable inhibitor of CXC Chemokine Receptor 4 (CXCR4) with potential antineoplastic activity. CXCR4 antagonist BKT140 selectively binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation, which may result in decreased tumor cell proliferation and migration. In addition, inhibition of CXCR4 may induce mobilization of hematopoietic cells from the bone marrow into blood. The G protein-coupled receptor CXCR4 plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; SDF-1/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

CXCR4 antagonist TG-0054  
An orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with receptor binding and hematopoietic stem cell-mobilization activities. CXCR4 inhibitor TG-0054 binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation; this may the mobilization of hematopoietic stem and progenitor cells from the bone marrow into blood. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; CXCL12/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

CXCR4 inhibitor MSX-122  
An orally bioavailable inhibitor of CXCR4 with potential antineoplastic and antiviral activities. CXCR4 inhibitor MSX-122 binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor-1 (SDF-1) to the CXCR4 receptor and receptor activation, which may result in decreased tumor cell proliferation and migration. CXCR4, a chemokine receptor belonging to the GPCR (G protein-coupled receptor) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; it is also a co-receptor for HIV entry into T cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

CXCR4 inhibitor POL6326  
An orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with receptor binding and hematopoietic stem cell-mobilization activities. CXCR4 inhibitor POL6326 binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation. This may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into blood. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; CXCL12/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cyanocobalamin  
An essential nutrient and natural water-soluble vitamin of the B-complex family that must combine with an intrinsic factor for absorption by the intestine. Cyanocobalamin is necessary for hematopoiesis, neural metabolism, DNA and RNA production, and carbohydrate, fat, and protein metabolism. B12 improves iron functions in the metabolic cycle and assists folic acid in choline synthesis. B12 metabolism is interconnected with that of folic acid. Vitamin B12 deficiency causes pernicious anemia, megaloblastic anemia, and neurologic lesions. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cyclin B1 peptide-pulsed autologous dendritic cell vaccine  
A cell-based cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with cyclin B1 peptide, with potential immunostimulatory and antineoplastic activities. Upon administration, cyclin B1 peptide-pulsed autologous dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and anti-cyclin B1 antibody responses against cyclin B1-expressing cancer cells, resulting in tumor cell lysis. Cyclin B1, a key regulator of the cell cycle and cell division, is overexpressed in a variety of cancer cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cyclin D modulator ON 013105  
A benzyl styryl sulfone analog, and a disodium phosphate ester prodrug of ON 013100, with potential antineoplastic activity. Upon hydrolysis, cyclin D modulator ON 013105 is converted to ON 013100, which blocks cyclin D mRNA translation and decreases protein expression of cyclin D. This may induce cell cycle arrest and apoptosis in cancer cells overexpressing cyclin D and eventually decrease tumor cell proliferation. This agent may exhibit synergistic antitumor activity in combination with other chemotherapeutic agents. Cyclin D, a member of the cyclin family of cell cycle regulators, plays a key role in cell cycle division and is often overexpressed in a variety of hematologic and solid tumors and is correlated with poor prognosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cyclodextrin-based polymer-camptothecin CRLX101  
A formulation of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, conjugated with to a hydrophilic, cyclodextrin-based linear polymer with potential antineoplastic activity. Upon intravenous administration, camptothecin is slowly released from the formulation at the tumor site and taken up by tumor cells. During the S phase of the cell cycle, camptothecin selectively stabilizes topoisomerase I-DNA covalent complexes, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. Compared to camptothecin alone, the cyclodextrin-based polymer formulation has a prolonged half life and greatly improves the biodistribution of camptothecin resulting in an accumulation of camptothecin at the tumor site, which enhances tumor exposure while greatly reducing toxic side effects. In addition, cyclodextrin-based polymer-camptothecin may be able to overcome certain kinds of multidrug resistance. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cycloleucine  
A non-metabolizable synthetic amino acid, formed through the cyclization of the amino acid leucine, with immunosuppressive, antineoplastic, and cytostatic activities. Cycloleucine competitively inhibits the enzyme methionine adenosyltransferase, resulting in the inhibition of S-adenosylmethionine (SAM) synthesis from methionine and ATP, and subsequent nucleic acid methylation and polyamine production; RNA, and perhaps to a lesser extent, DNA biosyntheses and cell cycle progression are finally disrupted. This agent is also a competitive inhibitor at the glycine modulatory site of the N-methyl-D-aspartate (NMDA) receptor. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cyclopentenyl cytosine  
A pro-drug carbocyclic analogue of cytidine with antineoplastic and antiviral activities. Cyclopentenyl cytosine (CPEC) is converted to the active metabolite cyclopentenyl cytosine 5'-triphosphate (CPEC-TP); CPEC-TP competitively inhibits cytidine triphosphate (CTP) synthase, thereby depleting intracellular cytidine pools and inhibiting DNA and RNA synthesis. This agent may also induce differentiation of some tumor cell types. The antiviral activity of this agent is broad-spectrum. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cyclophosphamide  
A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cyclosporine  
A natural cyclic polypeptide immunosuppressant isolated from the fungus Beauveria nivea. The exact mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cyclosporine ophthalmic emulsion  
An topical ophthalmic formulation containing cyclosporine, an undecapeptide produced by the fungus Beauveria nivea, with immunosuppressant and anti-inflammatory activities. The exact therapeutic mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Cyfos  
(Other name for: ifosfamide)

Cyklokapron  
(Other name for: tranexamic acid)

CYL-02 plasmid DNA  
A gene transfer preparation of a plasmid DNA encoding mouse somatostatin receptor subtype 2 (sst2) and a fusion protein of human deoxycytidine kinase (DCK) and uridine monophosphate kinase (UMK), complexed to a synthetic polycationic carrier, polyethylenimine, with antineoplastic adjuvant application. Upon administration, CYL-02 plasmid DNA expresses DCK::UMK fusion protein that converts gemcitabine into its toxic phosphorylated metabolite. Expression of sst2 protein by this agent could induce both antioncogenic and local antitumor bystander effects. A loss of sst2 gene expression often is found in pancreatic and colorectal cancers, and is the receptor for somatostatin which negatively regulates a number of processes such as epithelial cell proliferation. Combination effects of these gene products allows for less chemotherapy to cause tumor cell lysis in not only the original tumor, but in distant tumors as well. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

CYP17 inhibitor CFG920  
An orally available inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential antiandrogen and antineoplastic activities. Upon oral administration, CYP17 inhibitor CFG920 inhibits the enzymatic activity of CYP17A1 in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1, localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cyproheptadine hydrochloride  
The hydrochloride salt of a synthetic methyl-piperidine derivative with antihistaminic and anti-serotoninergic properties. Cyproheptadine competes with free histamine (HA) for binding at HA-receptor sites, thereby competitively antagonizing histamine stimulation of HA-receptors in the gastrointestinal tract, large blood vessels, and bronchial smooth muscle. This agent also competes with free serotonin for binding at serotonin receptor sites. Cyproheptadine exhibits anticholinergic and sedative properties and has been shown to stimulate appetite and weight gain. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cyproterone acetate  
The acetate salt of a synthetic steroidal antiandrogen with weak progestational and antineoplastic activities. Cyproterone binds the androgen receptor (AR), thereby preventing androgen-induced receptor activation in target tissues and inhibiting the growth of testosterone-sensitive tumor cells. This agent also exerts progestational agonist properties at the level of the pituitary that reduce luteinizing hormone (LH), resulting in reductions in testicular androgen secretion and serum testosterone levels. Treatment with cyproterone alone results in incomplete suppression of serum testosterone levels. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Cyren A  
(Other name for: diethylstilbestrol)

cysteine-rich non-denatured whey protein isolate IMN1207  
A biologically active, cysteine-rich, undenatured, bovine whey-based protein isolate with potential anti-cachexia and glutathione-enhancing properties. Upon administration of cysteine-rich whey protein isolate, cystine and glutamylcystine are taken up by cells and release free cysteine. The available cysteine allows cells to synthesize glutathione (GSH), a tripeptide made from amino acids glycine, glutamate and cysteine, thereby maintaining and increasing intracellular GSH concentrations. GSH plays a major role as an antioxidant, thereby protecting cells from oxidative damage due to harmful substances such as free radicals and reactive oxygen compounds. As IMN 1207 is rich in protein, this agent may prevent weight loss and increase body weight and strength. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cytarabine  
An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cytochlor  
A radio-sensitizing pyrimidine nucleoside with potential antineoplastic activity. Cytochlor is metabolized first to a phosphate derivative, CldCMP, by the enzyme deoxycytidine kinase and then to the active uracyl derivative, CldUMP, by the enzyme dCMP deaminase; deoxycytidine kinase and dCMP deaminase have been found in abnormally high concentrations in most cancers. CldUMP, the active metabolite, incorporates into DNA and, upon exposure to radiation, induces the formation of uracil radicals and double-strand DNA breaks. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cytokine-induced killer cells  
A preparation of autologous lymphocytes with potential immunopotentiating and antineoplastic activities. Cytokine-induced killer (CIK) cells are CD3-and CD56-positive, non-major histocompatibility complex (MHC)-restricted, natural killer (NK)-like T lymphocytes, generated ex-vivo by incubation of peripheral blood lymphocytes (PBLs) with anti-CD3 monoclonal antibody, interleukin (IL)-2, IL-1, and interferon gamma (IFN-gamma) and then expanded. When reintroduced back to patients after autologous stem cell transplantation, CIK cells may recognize and kill tumor cells associated with minimal residual disease (MRD). CIK cells may have enhanced cytotoxic activity compared to lymphokine-activated killer (LAK) cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cytomegalovirus IE-1-specific cytotoxic T lymphocytes  
Cytotoxic T-lymphocytes (CTLs), specifically reactive to the cytomegalovirus (CMV) immediate early-1 (IE-1) protein, with immunomodulating activity. Adoptive immunotherapy with cytomegalovirus IE-1-specific cytotoxic T lymphocytes may help reconstitute CD8+ cytomegalovirus-specific CTL responses in CMV-infected immunocompromised hosts. IE-1 is one of the first CMV antigens expressed by CMV-infected cells, predominantly inducing a CD8+ CTL response. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

cytomegalovirus pp65-specific cytotoxic T lymphocytes  
Cytotoxic T lymphocytes (CTLs) specifically reactive to the cytomegalovirus (CMV) phosphoprotein pp65 with potential antiviral activity. To prepare CMV pp65-specific cytotoxic T lymphocytes in vitro, dendritic cells (DCs) are pulsed with CMV pp65 epitopes and then used to stimulate and propagate CMV pp65-specific cytotoxic T lymphocytes from peripheral blood mononuclear cells (PBMNCs); the CMV pp65-specific cytotoxic T lymphocyte population is then expanded so as to be sufficient for use in adoptive T lymphocyte therapy. When administered into a patient post-allogeneic hematopoietic stem cell transplantation, this agent may elicit a specific CTL response against CMV-infected host cells, which may result in the resolution of CMV infection. The CMV pp65 protein (65 kDa lower matrix phosphoprotein), the primary component of the enveloped subviral particle, is an immunodominant target for helper and cytotoxic T lymphocyte responses to CMV. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Cytomel  
(Other name for: liothyronine sodium)

Cytosar-U  
(Other name for: cytarabine)

Cytoxan  
(Other name for: cyclophosphamide)

Back to TopBack to Top

< Previous  1 2